PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2018.10062018243299-301Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?Yong Kyun Chohttp://e-cmh.org/upload/pdf/cmh-2018-1006.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2018.1006, http://e-cmh.org/upload/pdf/cmh-2018-1006.pdf
Clinical and Molecular Hepatology10.3350/cmh.2018.00062018243331-338Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver diseaseSaba Sayari, Hassan Neishaboori, Maryam Jameshoranihttp://e-cmh.org/upload/pdf/cmh-2018-0006.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2018.0006, http://e-cmh.org/upload/pdf/cmh-2018-0006.pdf
Clinical Liver Disease10.1002/cld.65201214104-107Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkersMazen Noureddin, Rohit Loombahttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcld.65
Alimentary Pharmacology & Therapeutics10.1111/j.1365-2036.2007.03246.x2007258883-889GI Epidemiology: nonalcoholic fatty liver diseaseP. ANGULOhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2007.03246.x
Clinical Liver Disease10.1002/cld.27201214112-113Natural history of nonalcoholic fatty liver diseaseRohini Mehta, Zobair M. Younossihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcld.27
Clinical Liver Disease10.1002/cld.66201214129-130Management of nonalcoholic fatty liver disease in childrenJean P. Mollestonhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcld.66
Clinical Liver Disease10.1002/cld.75201214125-128Pediatric nonalcoholic fatty liver disease: Prevalence, diagnosis, risk factors, and managementStavra A. Xanthakos, Rohit Kohlihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcld.75
Talanta10.1016/j.talanta.2011.04.0512011851673-680Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation productRamzia I. El-Bagary, Ehab F. Elkady, Bassam M. Ayoubhttps://api.elsevier.com/content/article/PII:S0039914011003808?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0039914011003808?httpAccept=text/plain
Metabolic Syndrome and Related Disorders10.1089/met.2012.01282013114243-250Effects of Sitagliptin on Nonalcoholic Fatty Liver Disease in Diet-Induced Obese RatsSelvihan Beysel Akaslan, Ceyla Konca Degertekin, Guldal Yilmaz, Nuri Cakir, Metin Arslan, Fusun Balos Torunerhttp://www.liebertpub.com/doi/full-xml/10.1089/met.2012.0128, http://www.liebertpub.com/doi/pdf/10.1089/met.2012.0128
Gastroenterology10.1016/s0016-5085(12)63936-520121425S-1017Tu1037 Dipeptidyl Peptidase- 4 (Dpp-4) Inhibitor (Sitagliptin) as a Novel Treatment Agent for Nonalcoholic Fatty Liver Disease Patients With Type 2 Diabetes MellitusWataru Tomeno, Masato Yoneda, Kento Imajo, Hironori Mawatari, Hiroyuki Kirikoshi, Satoru Saito, Wataru Shibata, Kyoko Yoneda, Hiroki Endo, Kensuke Kubota, Atsushi Nakajimahttps://api.elsevier.com/content/article/PII:S0016508512639365?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508512639365?httpAccept=text/plain